{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:48:40Z","timestamp":1761554920608,"version":"build-2065373602"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20POST35210968"],"award-info":[{"award-number":["20POST35210968"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08HL145019"],"award-info":[{"award-number":["K08HL145019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK127073"],"award-info":[{"award-number":["K23DK127073"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.hfc.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:18:55Z","timestamp":1655407135000},"page":"415-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding Myocardial Metabolism in the Context of Cardio-Oncology"],"prefix":"10.1016","volume":"18","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsu-Zsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagvi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.hfc.2022.02.004_bib1","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.hfc.2022.02.004_bib2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl 5","key":"10.1016\/j.hfc.2022.02.004_bib3","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.004_bib4","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hfc.2022.02.004_bib5","doi-asserted-by":"crossref","first-page":"8863789","DOI":"10.1155\/2021\/8863789","article-title":"Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: effects of preventive strategies","volume":"2021","author":"Carrasco","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.hfc.2022.02.004_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.dnarep.2018.01.005","article-title":"DNA damage in blood cells in relation to chemotherapy and nutritional status in colorectal cancer patients-A pilot study","volume":"63","author":"Kv\u00e6rner","year":"2018","journal-title":"DNA Repair (Amst)"},{"issue":"23","key":"10.1016\/j.hfc.2022.02.004_bib7","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1182\/blood.V126.23.4559.4559","article-title":"Iron deficiency anemia is common in patients receiving chemotherapy","volume":"126","author":"Ahmad","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.004_bib8","doi-asserted-by":"crossref","first-page":"C744","DOI":"10.1152\/ajpcell.00002.2018","article-title":"Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress","volume":"315","author":"Guigni","year":"2018","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.hfc.2022.02.004_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.redox.2017.04.018","article-title":"Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism","volume":"12","author":"Kalyanaraman","year":"2017","journal-title":"Redox Biol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.004_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1389200216888150915112039","article-title":"Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines","volume":"16","author":"Edwardson","year":"2015","journal-title":"Curr Drug Metab"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.004_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A\u00a0critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hfc.2022.02.004_bib13","first-page":"45","article-title":"Anthracyclines","volume":"11","author":"Sinha","year":"1990","journal-title":"Cancer Chemother Biol Response Modif"},{"key":"10.1016\/j.hfc.2022.02.004_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.uct.2008.02.001","article-title":"Topoisomerase I.I. Inhibitors","volume":"3","author":"Hande","year":"2008","journal-title":"Update Cancer Ther"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0026-895X(25)12344-4","article-title":"Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms","volume":"27","author":"Muindi","year":"1985","journal-title":"Mol Pharmacol"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.004_bib16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1248\/yakushi.127.1837","article-title":"Mechanism of DNA damage and apoptosis induced by anticancer drugs through generation of reactive oxygen species","volume":"127","author":"Mizutani","year":"2007","journal-title":"Yakugaku Zasshi"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","article-title":"Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?","volume":"53","author":"Sawyer","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.004_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.chembiol.2012.08.011","article-title":"Bacterial inactivation of the anticancer drug doxorubicin","volume":"19","author":"Westman","year":"2012","journal-title":"Chem Biol"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.004_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"issue":"25","key":"10.1016\/j.hfc.2022.02.004_bib20","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.004_bib21","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cortes-Funes","year":"2007","journal-title":"Cardiovasc Toxicol"},{"issue":"1\u20132","key":"10.1016\/j.hfc.2022.02.004_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1007094214460","article-title":"Adriamycin-induced heart failure: mechanism and modulation","volume":"207","author":"Singal","year":"2000","journal-title":"Mol Cell Biochem"},{"issue":"22","key":"10.1016\/j.hfc.2022.02.004_bib24","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.004_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11886-013-0362-6","article-title":"Cardiac toxicity of anticancer agents","volume":"15","author":"Colombo","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.hfc.2022.02.004_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0005-2760(94)00082-4","article-title":"Regulation of fatty acid oxidation in the mammalican heart in health and disease","volume":"1213","author":"Lopaschuk","year":"1994","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol Rev"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.004_bib28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/CIRCHEARTFAILURE.112.000228","article-title":"Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy","volume":"6","author":"Zhang","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacc.2007.10.021","article-title":"Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options","volume":"51","author":"Witteles","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-020-00812-1","article-title":"Metabolic aspects of anthracycline cardiotoxicity","volume":"22","author":"Russo","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.004_bib31","doi-asserted-by":"crossref","first-page":"H1693","DOI":"10.1152\/ajpheart.00854.2012","article-title":"Insulin resistance protects the heart from fuel overload in dysregulated metabolic states","volume":"305","author":"Taegtmeyer","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/MCB.00983-10","article-title":"Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways","volume":"31","author":"Long","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/B:REMD.0000021433.63915.bb","article-title":"AMP-activated protein kinase: a master switch in glucose and lipid metabolism","volume":"5","author":"Hardie","year":"2004","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/cvr\/cvs134","article-title":"Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress","volume":"95","author":"Gratia","year":"2012","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib35","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41598-019-38986-w","article-title":"Cardiac molecular pathways influenced by doxorubicin treatment in mice","volume":"9","author":"Bulten","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.004_bib36","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1111\/jcmm.15305","article-title":"Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions","volume":"24","author":"Osataphan","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.004_bib37","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"21","key":"10.1016\/j.hfc.2022.02.004_bib38","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/0006-2952(80)90050-7","article-title":"Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity","volume":"29","author":"Goormaghtigh","year":"1980","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12944-019-1151-z","article-title":"The role of adipose triglyceride lipase in lipid and glucose homeostasis: lessons from transgenic mice","volume":"18","author":"Trites","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0005-2728(99)00011-0","article-title":"Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration","volume":"1411","author":"Serrano","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib41","doi-asserted-by":"crossref","first-page":"H434","DOI":"10.1152\/ajpheart.00253.2014","article-title":"Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure","volume":"309","author":"Lauritzen","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2007.04.106","article-title":"Simple quantitative detection of mitochondrial superoxide producton in live cells","volume":"358","author":"Mukhopadhyay","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.004_bib43","doi-asserted-by":"crossref","first-page":"H1466","DOI":"10.1152\/ajpheart.00795.2008","article-title":"Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in\u00a0vivo and in\u00a0vitro","volume":"296","author":"Mukhopadhyay","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.004_bib44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000048192.52098.DD","article-title":"Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction","volume":"107","author":"Pacher","year":"2003","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.004_bib45","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.freeradbiomed.2009.03.011","article-title":"Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway","volume":"46","author":"Danz","year":"2009","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1124\/jpet.112.198358","article-title":"Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways","volume":"343","author":"Jirkovsky","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.hfc.2022.02.004_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2014.05.017","article-title":"Cardioprotection against doxorubicin by metallothionein is associated with preservation of mitochondrial biogenesis involving PGC1alpha pathway","volume":"737","author":"Guo","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.004_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: implications beyond ATP production","volume":"113","author":"Abel","year":"2013","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.004_bib49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.celrep.2015.09.054","article-title":"A\u00a0metabolic signature of mitochondrial dysfunction revealed through a monogenic form of Leigh syndrome","volume":"13","author":"Thompson Legault","year":"2015","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cmet.2013.12.003","article-title":"\u03b2-Aminoisobutyric acid induces browning of white fat and hepatic \u03b2-oxidation and is inversely correlated with cardiometabolic risk factors","volume":"19","author":"Roberts","year":"2014","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12265-019-09897-y","article-title":"Changes in citric acid cycle and nucleoside metabolism are associated with anthracycline cardiotoxicity in patients with breast cancer","volume":"13","author":"Asnani","year":"2020","journal-title":"J\u00a0Cardiovasc Transl Res"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0140-y","article-title":"Adriamycin-induced oxidative mitochondrial cardiotoxicity","volume":"23","author":"Berthiaume","year":"2007","journal-title":"Cell Biol Toxicol"},{"issue":"4 Suppl 10","key":"10.1016\/j.hfc.2022.02.004_bib53","first-page":"10","article-title":"The role of iron in doxorubicin-induced cardiomyopathy","volume":"25","author":"Myers","year":"1998","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.004_bib55","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/hdy.2010.54","article-title":"Epigenetics and gene expression","volume":"105","author":"Gibney","year":"2010","journal-title":"Heredity (Edinb)"},{"issue":"7766","key":"10.1016\/j.hfc.2022.02.004_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41586-019-1411-0","article-title":"Advances in epigenetics link genetics to the environment and disease","volume":"571","author":"Cavalli","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.004_bib59","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/or.2013.2913","article-title":"Epigenetic regulation and cancer (review)","volume":"31","author":"Chen","year":"2014","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: past, present and future","volume":"5","author":"Yoo","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.004_bib62","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hfc.2022.02.004_bib64","doi-asserted-by":"crossref","first-page":"102089","DOI":"10.1016\/j.redox.2021.102089","article-title":"Role of acetylation in doxorubicin-induced cardiotoxicity","volume":"46","author":"Li","year":"2021","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib65","doi-asserted-by":"crossref","first-page":"87.e1-6","DOI":"10.1016\/j.amjmed.2009.06.022","article-title":"Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy","volume":"123","author":"Redig","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.hfc.2022.02.004_bib66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib67","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"27","key":"10.1016\/j.hfc.2022.02.004_bib68","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hfc.2022.02.004_bib69","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.hfc.2022.02.004_bib70","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2022.02.004_bib71","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.hfc.2022.02.004_bib72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"10.1016\/j.hfc.2022.02.004_bib73","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/ijms20225792","article-title":"PI3K\/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases","volume":"20","author":"Hillmann","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.004_bib74","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1634\/theoncologist.2015-0248","article-title":"Hyperglycemia and phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin (PI3K\/AKT\/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management","volume":"21","author":"Khan","year":"2016","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.004_bib75","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.hfc.2022.02.004_bib76","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib77","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cpt.552","article-title":"Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approaches","volume":"101","author":"Brown","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hfc.2022.02.004_bib78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yjmcc.2021.12.013","article-title":"Hypoxia signaling and oxygen metabolism in cardio-oncology","volume":"165","author":"Baik","year":"2022","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.004_bib79","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.004_bib80","doi-asserted-by":"crossref","first-page":"e149415","DOI":"10.1172\/JCI149415","article-title":"Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease","volume":"131","author":"Kirk","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib81","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1038\/cddis.2014.32","article-title":"Knockdown of BAG3 induces epithelial-mesenchymal transition in thyroid cancer cells through ZEB1 activation","volume":"5","author":"Meng","year":"2014","journal-title":"Cell Death Dis"},{"issue":"21","key":"10.1016\/j.hfc.2022.02.004_bib82","doi-asserted-by":"crossref","first-page":"15673","DOI":"10.18632\/oncotarget.24590","article-title":"BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer","volume":"9","author":"Shields","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.hfc.2022.02.004_bib83","doi-asserted-by":"crossref","first-page":"516518","DOI":"10.1155\/2014\/516518","article-title":"BAG3 and HIF-1 \u03b1 coexpression detected by immunohistochemistry correlated with prognosis in hepatocellular carcinoma after liver transplantation","volume":"2014","author":"Xiao","year":"2014","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.004_bib84","doi-asserted-by":"crossref","first-page":"e1173","DOI":"10.1038\/cddis.2014.143","article-title":"BAG3 protein expression in melanoma metastatic lymph nodes correlates with patients' survival","volume":"5","author":"Guerriero","year":"2014","journal-title":"Cell Death Dis"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.004_bib85","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/emm.2013.85","article-title":"Cancer cell metabolism: implications for therapeutic targets","volume":"45","author":"Jang","year":"2013","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.004_bib86","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.004_bib87","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: a systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaccao.2019.08.014","article-title":"Pre-diagnosis exercise and cardiovascular events in primary breast cancer: women\u2019s health initiative","volume":"1","author":"Okwuosa","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.004_bib89","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41467-020-20743-7","article-title":"Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models","volume":"12","author":"Das","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.004_bib90","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/XCE.0000000000000228","article-title":"Exercise, cancer and cardiovascular disease: what should clinicians advise?","volume":"10","author":"Zimmerman","year":"2020","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.hfc.2022.02.004_bib91","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.004_bib92","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacbts.2021.05.008","article-title":"Cardio-oncology: understanding the intersections between cardiac metabolism and cancer biology","volume":"6","author":"Karlstaedt","year":"2021","journal-title":"JACC Basic Transl Sci"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:43:31Z","timestamp":1761554611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713622000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1551713622000058"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.004","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Myocardial Metabolism in the Context of Cardio-Oncology","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}